CBD-C6 Cannabinoid Isolation for Pharmaceutical Anticonvulsant Use
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cannabinoid preparations from cannabis plants are unsuitable for pharmaceutical use due to their complex composition and variability, and the therapeutic potential of minor cannabinoids like cannabidiol-C6 (CBD-C6) has not been fully explored.
Innovation Solution
CBD-C6 is extracted and purified from cannabis plants or produced synthetically, with doses ranging from 1 mg/kg/day to 1500 mg/kg/day, and formulated into a medicament or composition with pharmaceutically acceptable excipients for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If crude extracts from cannabis plants containing CBD are used, then the preparation contains the desired cannabinoid compounds, but the composition is complex and unsuitable for pharmaceutical formulations
Solution Approach 1:
The patent extracts and isolates specific cannabinoid compounds (CBD and CBD-C6) from the complex cannabis plant matrix. This involves separating the desired cannabinoids from other plant constituents through purification processes, thereby obtaining a simplified composition suitable for pharmaceutical use while maintaining the therapeutic cannabinoid content
Solution Approach 2:
The patent segments the complex cannabinoid profile of cannabis by focusing on and isolating specific individual compounds (CBD and CBD-C6) rather than using the whole extract. This segmentation allows for controlled pharmaceutical formulations with defined active ingredients while eliminating the complexity of the complete plant extract
2Object-affected harmful factors
If all compounds other than CBD are removed from plant derived cannabinoids, then psychoactive compounds such as THC are eliminated, but the therapeutic potential of minor cannabinoids like CBD-C6 is lost
Solution Approach 1:
The patent applies local quality by selectively retaining specific cannabinoid compounds (CBD and CBD-C6) while removing others. Instead of uniformly eliminating all non-CBD compounds, the invention specifically preserves CBD-C6 which has distinct therapeutic properties, thereby maintaining beneficial minor cannabinoids while eliminating unwanted psychoactive compounds through selective purification
3Reliability
If CBD-C6 is extracted and purified from cannabis plants, then the compound can be used in pharmaceutical formulations, but the production process becomes more complex
Solution Approach 1:
The patent employs extraction solvents and purification intermediaries to isolate CBD-C6 from the cannabis plant matrix. These intermediary substances facilitate the separation and purification processes, enabling the获得 of pharmaceutical-grade CBD-C6 while managing the complexity of the production process through established chemical extraction and purification methodologies
Data Source
AI summary
The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.